...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
【24h】

Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.

机译:心肌肌苷结合蛋白C突变和肥厚性心肌病:HAPLOUSUCK,乳化磷酸化和心肌细胞功能障碍。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Mutations in the MYBPC3 gene, encoding cardiac myosin-binding protein C (cMyBP-C), are a frequent cause of familial hypertrophic cardiomyopathy. In the present study, we investigated whether protein composition and function of the sarcomere are altered in a homogeneous familial hypertrophic cardiomyopathy patient group with frameshift mutations in MYBPC3 (MYBPC3(mut)). METHODS AND RESULTS: Comparisons were made between cardiac samples from MYBPC3 mutant carriers (c.2373dupG, n=7; c.2864_2865delCT, n=4) and nonfailing donors (n=13). Western blots with the use of antibodies directed against cMyBP-C did not reveal truncated cMyBP-C in MYBPC3(mut). Protein expression of cMyBP-C was significantly reduced in MYBPC3(mut) by 33+/-5%. Cardiac MyBP-C phosphorylation in MYBPC3(mut) samples was similar to the values in donor samples, whereas the phosphorylation status of cardiac troponin I was reduced by 84+/-5%, indicating divergent phosphorylation of the 2 main contractile target proteins of the beta-adrenergic pathway. Force measurements in mechanically isolated Triton-permeabilized cardiomyocytes demonstrated a decrease in maximal force per cross-sectional area of the myocytes in MYBPC3(mut) (20.2+/-2.7 kN/m(2)) compared with donor (34.5+/-1.1 kN/m(2)). Moreover, Ca(2+) sensitivity was higher in MYBPC3(mut) (pCa(50)=5.62+/-0.04) than in donor (pCa(50)=5.54+/-0.02), consistent with reduced cardiac troponin I phosphorylation. Treatment with exogenous protein kinase A, to mimic beta-adrenergic stimulation, did not correct reduced maximal force but abolished the initial difference in Ca(2+) sensitivity between MYBPC3(mut) (pCa(50)=5.46+/-0.03) and donor (pCa(50)=5.48+/-0.02). CONCLUSIONS: Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins, and reduced maximal force-generating capacity of cardiomyocytes. The enhanced Ca(2+) sensitivity in MYBPC3(mut) is due to hypophosphorylation of troponin I secondary to mutation-induced dysfunction.
机译:背景:编码心肌霉菌蛋白C(CMYBP-C)的MyBPC3基因中的突变是家族肥厚性心肌病的常见原因。在本研究中,我们研究了肉瘤的蛋白质组成和功能是否在均匀的家族肥厚性心肌病患者组中改变了MyBPC3中的框架突变(MyBPC3(mut))。方法和结果:来自MYBPC3突变载体的心脏样品(C.2373DUPG,N = 7; C.2864_2865DelCT,N = 4)和非缺少供体(n = 13)之间进行比较。使用针对CMYBP-C的抗体的Western印迹没有揭示MyBPC3(mut)中截短的CMYBP-C. MYBPC3(MUT)的CMYBP-C的蛋白表达明显减少33 +/- 5%。 MyBPC3(mut)样品中的心脏MyBP-C磷酸化类似于供体样品中的值,而心肌肌钙蛋白I的磷酸化状态降低了84 +/- 5%,表明2个主要收缩靶蛋白的发散磷酸化β-肾上腺素能途径。机械隔离的Triton - 渗透性心肌细胞的力测量表明,与供体相比,MyBPC3(mut)中肌细胞的横截面积(20.2 +/- 2.7kn / m(2))的横截面积的最大力降低(34.5 +/- 1.1 KN / M(2))。此外,在施主中(PCA(50)= 5.62 +/- 0.04),Ca(2+)敏感性较高(PCA(50)= 5.62 +/- 0.04),与减少的心肌肌钙蛋白I磷酸化一致。用外源蛋白激酶A治疗,以模仿β-肾上腺素能刺激,并未校正最大力的降低,但废除了MYBPC3(MUT)之间的Ca(2+)敏感性的初始差异(PCA(50)= 5.46 +/- 0.03)和供体(PCA(50)= 5.48 +/- 0.02)。结论:FRAMESHIFT MYBPC3突变引起臭氧水能,减少收缩蛋白的磷酸化,并降低了心肌细胞的最大力产生能力。 MyBPC3(mut)中增强的Ca(2+)敏感性是由于肌钙蛋白I继发于突变诱导的功能障碍的次磷酸化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号